Laden…
Evidence-based risk assessment and known adverse effects
Risk Classification: Unclassified
The risk profile of Dipropyltryptamine has not been fully characterised. Insufficient scientific data is available to draw definitive conclusions.
Neurotoxicity
none_known
The following substances carry an elevated risk of adverse interactions with Dipropyltryptamine. This list is not exhaustive.
For a full interaction overview, see the Interactions page.
combinations
Tryptamin-Klasse: besonders gefährlich in Kombination mit MAO-Hemmern (inkl. Harmalin aus Ayahuasca)
dosing
AMT: extrem lange Wirkdauer (12–24h) — volle 2 Tage freie Zeit einplanen
dosing
Niedrig einsteigen — Tryptamine variieren stark in Potenz, genaue Dosierung kritisch
setting
Tripsitter bei Erstkonsum obligatorisch
dosing
Nüchtern konsumieren — Essen verlangsamt und verändert Resorption
combinations
Keine Kombination mit Lithium (Krampfrisiko)
Disclaimer: This information is provided for educational purposes only and does not constitute medical advice. If you have concerns about substance use, please consult a qualified healthcare professional or contact a local drug support service.